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Abstract
Background: The promise of modern personalized medicine is to use molecular and clinical information to better diagnose,
manage, and treat disease, on an individual patient basis. These functions are predominantly enabled by molecular
signatures, which are computational models for predicting phenotypes and other responses of interest from high-
throughput assay data. Data-analytics is a central component of molecular signature development and can jeopardize the
entire process if conducted incorrectly. While exploratory data analysis may tolerate suboptimal protocols, clinical-grade
molecular signatures are subject to vastly stricter requirements. Closing the gap between standards for exploratory versus
clinically successful molecular signatures entails a thorough understanding of possible biases in the data analysis phase and
developing strategies to avoid them.
Methodology and Principal Findings: Using a recently introduced data-analytic protocol as a case study, we provide an in-
depth examination of the poorly studied biases of the data-analytic protocols related to signature multiplicity, biomarker
redundancy, data preprocessing, and validation of signature reproducibility. The methodology and results presented in this
work are aimed at expanding the understanding of these data-analytic biases that affect development of clinically robust
molecular signatures.
Conclusions and Significance: Several recommendations follow from the current study. First, all molecular signatures of a
phenotype should be extracted to the extent possible, in order to provide comprehensive and accurate grounds for
understanding disease pathogenesis. Second, redundant genes should generally be removed from final signatures to
facilitate reproducibility and decrease manufacturing costs. Third, data preprocessing procedures should be designed so as
not to bias biomarker selection. Finally, molecular signatures developed and applied on different phenotypes and
populations of patients should be treated with great caution.
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Introduction
The promise of personalized medicine is to use molecular and
clinical information to better diagnose, manage, and treat disease
on an individual patient basis. These functions are predominantly
enabled by molecular signatures that are computational models for
predicting phenotypes and other responses of interest from high-
throughput assay data. Many molecular signatures have been
developed to date from high-throughput data, and some of them
have passed regulatory approval and are currently used in clinical
practice [1,2]. However, data-analytics for development of
clinically robust molecular signatures is challenging and can
undermine the entire effort, if it is not conducted correctly [3].
Whereas substantial tolerance to suboptimal data-analytic proto-
cols (e.g., not perfectly unbiased, slightly underpowered, leading to
redundant biomarkers, etc.) exists for exploratory research, extra
care has to be taken for development of molecular signatures for
clinical use. Clinical-grade molecular signatures are subject to vastly
more stringent operating quality requirements since such signa-
tures may guide life-and-death decisions. Clinical-grade signatures
must also satisfy higher cost-effectiveness and accessibility
requirements. In addition, succumbing to data analysis biases
can prevent otherwise promising molecular signatures from
reaching the market by not meeting requirements for the
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development of clinical-grade molecular signatures is a very
important problem with characteristics distinctively different from
those of exploratory data-analytics.
Closing the gap between standards for exploratory versus
clinically successful molecular signatures entails a thorough
understanding of possible biases in the data analysis phase and
developing strategies to avoid them. Previous research has
identified several biases of data-analytics for molecular signature
development which include: using unsupervised methods (e.g.,
clustering) for development of molecular signatures [4]; biasing
signature accuracy estimation by conducting supervised gene
selection both on training and testing data [4,5]; biasing selection
of biomarkers by inappropriately using clinical covariates [6]; and
failing to identify predictive signal by using underpowered data-
analytic protocols [7] or conducting gene selection for a different
phenotype [8].
In the present work we aim to expand the understanding of
data-analytic biases that critically affect development of clinically
robust molecular signatures. As a case study, we use a recently
introduced data-analytic protocol that led to development of a 30-
gene ‘‘acute respiratory viral response’’ molecular signature for
distinguishing individuals with symptomatic acute respiratory viral
infections from uninfected individuals [9]. In a preliminary work
we briefly mentioned possible biases of the prior data-analytic
protocol related to estimation of signature predictive accuracy,
validation of signature in independent data, biomarker redundan-
cy, and signature multiplicity [10]. Here we provide an in-depth
technical treatment of these and other biases with an emphasis on
what created them and how to avoid them in similar future
research. We demonstrate our findings using three datasets that
have been recently used for development of molecular signatures
of infectious diseases [9,11,12]. The conclusions of the present
study extend well beyond the development of gene expression-
based molecular signature of acute respiratory viral infections; the
results readily generalize to other protocols, phenotypes, and assay
platforms.
Materials and Methods
Microarray gene expression datasets
As the main dataset for development of molecular signatures in
this work we used the microarray gene expression dataset of Zaas
et al. [9] that was downloaded from the Gene Expression Omnibus
(GEO) under the accession number GSE17156. This dataset
contained 113 normalized gene expression profiles of peripheral
blood samples collected from subjects at two time points: (i) prior
to inoculation with one of three respiratory viruses (HRV, RSV
and influenza A) and (ii) at the peak time of symptoms. The pre-
inoculation samples are referred to as baseline or unexposed samples.
The post-inoculation samples are referred to as peak time or exposed.
One of the 113 samples (GSM429232) did not have a matching
baseline gene expression profile and was excluded from analysis.
Thus, the dataset used in this work contained in total 112 gene
expression profiles. Their break down by virus type and time of
collection (baseline or peak) is shown in Table 1. All subjects were
healthy and uninfected at baseline with some remaining
asymptomatic after the viral exposure, while others developed
symptoms of a viral infection as shown in Table 1. Exposed
subjects were considered asymptomatic if their modified Jackson
score [13] was below 6 over the 5 days of observation and if the
viral shedding was not detected after the first 24 hours post
inoculation [9]. Thus, following Zaas et al. [9], we also consider
asymptomatic subjects to be uninfected.
The dataset of Ramilo et al. [12] was used for an independent
validation of panviral molecular signatures developed in the
present work and was also obtained from GEO (accession number
GSE6269). This dataset contained gene expression profiles
obtained from peripheral blood leukocytes of mostly pediatric
patients with acute infections caused by either influenza A, or one
of three bacterial pathogens: (i) Staphylococcus aureus, (ii) Streptococcus
pneumoniae, both Gram-positive bacteria, and (iii) Escherichia coli,a
Gram-negative bacterium. The data of Ramilo et al. [12] also
contained gene expression profiles of 6 healthy controls.
Distribution of the number of gene expression profiles for each
group of patients is shown in Table 1.
Finally, a third dataset was used to demonstrate that the overall
conclusions of the present paper pertaining to data-analytic
protocols, generalize beyond the domain of acute respiratory viral
infections. This dataset originated from a recent study aimed at
development of molecular signatures for diagnosis of invasive
Candidemia, one of the most common bloodstream infections in
the U.S. [11]. The dataset contained 72 normalized gene
expression profiles of peripheral blood samples from mice and
was downloaded from GEO (accession number GSE20524). Out
of 72 samples, 46 were infected with C. albicans, 9 were infected
with S. aureus bacteremia (the most common bloodstream infection
occurring in patients at risk for Candidemia), and 17 were healthy
controls.
Simulated data used for evaluation of methods for
development of molecular signatures under the
condition of signature multiplicity
In order to compare, in a controlled setting, methods for
developing molecular signatures considered in this work, we use a
simulated dataset TIED with exactly known causal relationships
between variables [14,15] and which was previously used in an
international causality challenge [16]. The data generating graph
is shown in Figure S1 and its parameterization is provided in
[14,15]. The dataset contains 750 observations and 1,000 variables
(999 genes and a phenotypic response variable). There are 72
distinct molecular signatures of the phenotype (i.e., sets of non-
redundant genes that carry maximal predictive information about
the phenotype and render it statistically independent of all other
genes). Each of these signatures carries equivalent information
about the phenotype and spans over 5 genes: gene X10 and one
gene from each of the four subsets {X1,X2,X3,X11}, {X5,X9},
{X12,X13,X14} and {X19,X20,X21}.
Table 1. Number of gene expression profiles corresponding
to each category of samples from the data of Zaas et al. [9]
and Ramilo et al. [12].
Infection type Zaas et al.
Ramilo
et al.
Asymptomatic Symptomatic
Rhinovirus (HRV) 10 9 N/A
Respiratory Syncytial Virus (RSV) 11 9 N/A
Influenza A 98 1 8
Bacterial (Staphylococcus aureus,
Streptococcus pneumoniae,
Escherichia coli)
N/A N/A 73
Unexposed (healthy uninfected) 56 6
doi:10.1371/journal.pone.0020662.t001
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the same phenotype
A perplexing phenomenon that characterizes high-throughput
data analysis is the ubiquitous multiplicity of molecular signatures
[17,18]. This phenomenon has far-reaching implications for
biological discovery and development of next generation patient
diagnostics and personalized treatments [15]. Therefore, it is
informative not only to show the existence of a single signature for
a given phenotype variable, but also to seek all possible maximally
predictive signatures that do not contain redundant genes. Such
analysis allows to improve discovery of the underlying biological
mechanisms by not missing genes that are implicated mechanis-
tically in the disease processes. Furthermore this analysis facilitates
separation of statistical instability from intrinsic information
equivalency [15].
To extract multiple molecular signatures, we apply a recently
introduced and provably correct algorithm TIE* that outputs the
complete set of maximally predictive and non-redundant signa-
tures independent of the data distribution [15]. TIE* is based on
Markov boundary induction which enables probabilistic modeling
of multiple signatures and formally connects them with the causal
graph (pathway) of the data generating process even when this
pathway is not known a priori [19–22]. TIE* has been shown to
have excellent sample and computational efficiency and to extract
signatures reproducible in independent datasets [15].
In this work, we use Generalized Local Learning (abbreviated as
GLL; specific instantiation: semi-interleaved HITON-PC without
symmetry correction) as the base Markov boundary algorithm in
TIE* [23,24]. This choice of the base algorithm was motivated by
its empirical performance in microarray gene expression and other
high-throughput data as well as its theoretical properties [23,24].
Under broad assumptions, GLL provably discovers non-redun-
dant genes that are located in the local pathway of the phenotype
variable [23,24]. GLL was run with the Fisher’s Z-test for
vanishing partial correlations at significance level a~5%, and with
max-k=1. The maximum cardinality of a subset of genes to be
excluded from the entire set of genes within each iteration in TIE*
was set to 5. Fisher’s Z-test was also used for evaluation of
candidate Markov boundaries in TIE* [15].
Once genes were selected, we completed the development of
molecular signatures by applying Support Vector Machine (SVM)
classifiers [25] implemented in LibSVM version 2.89 (http://
www.csie.ntu.edu.tw/,cjlin/libsvm). SVMs were applied with the
linear kernel and the cost parameter C=100.
Method for assessing redundancy of genes in a
molecular signature
A gene is considered to be redundant with respect to the
phenotype if its removal from the molecular signature does not
decrease the signature’s predictive accuracy. Thus, in principle,
redundancy can be assessed using so-called wrapper algorithms
[26]. However, wrapping techniques are prone to overfitting due
to a very large number of comparisons, and in small-sample
settings they can falsely conclude that different sets of biomarkers
have the same predictive accuracy when in reality they do not
[23]. Thus we test the redundancy of genes using a more
conservative approach with the following two steps. First, we find
genes that do not carry any association with the phenotype
conditioned on another gene from the signature using Fisher’s Z-
test [27] at significance level a~5%. Once we identify such genes,
we do not readily exclude them from the molecular signature but
do so only if their removal does not lead to decrease in predictive
accuracy of the signature (as measured by the area under ROC
curve and compared using statistical test of Delong et al. [28]). The
assessment of redundancy is performed by repeated cross-
validation [29] in training data only. The resulting non-redundant
signature is subsequently validated in an independent data and its
predictive accuracy is compared to the accuracy of the original
signature (which contains both redundant and non-redundant
genes).
Method for assessing biases of data preprocessing after
standard microarray data normalization
In order to study the effects on gene selection of different data
preprocessing schemes (discussed below) following the standard
microarray data normalization (e.g., by the RMA method
[30,31]), we employ permutation testing with 10,000 permutations
of the phenotype variable under the null hypothesis of no
association between genes and the phenotype. On each permu-
tation, we apply a given data preprocessing method and then
perform gene selection using a two-sample t-test with the false
discovery rate (FDR) correction at level 0.2 [32,33]. This
procedure allows us to quantify the extent to which different
preprocessing methods may bias gene selection. Under the
assumption that the null hypothesis holds in the data and if a
preprocessing method does not bias gene selection, we would
expect none of the genes to be selected as significantly associated
with the phenotype. However, since we are simulating the null
hypothesis by permuting the phenotype variable in a real dataset
where expression of different genes may not be independent of
others and where small sample effects may be present, a small
number of genes may be deemed significantly associated with the
phenotype even under an unbiased preprocessing method.
Because such effects are expected to be minimal when no
preprocessing is performed, we use it as a baseline against which
all other preprocessing methods can be evaluated. If after some
preprocessing, the number of significantly associated genes
increases relative to no preprocessing, this signals that the applied
preprocessing method may bias gene selection by potentially
increasing the number of false positives.
Data preprocessing methods
We consider six different data preprocessing methods that are
applied in the current study after the standard microarray data
normalization by RMA. The first method establishes a baseline
and consists of no preprocessing. The second method was used in
the protocol of Zaas et al. [9] and consists of centering the data by
subtracting the grand mean from the entire gene expression
dataset. The third method standardizes each gene expression
variable to have zero mean and standard deviation of one. The
fourth method rescales each gene expression variable to lie in the
interval [0,1]. These four methods are commonly used in gene
expression analysis and are unsupervised in a sense that they do
not take into account the phenotype information, and thus are
unlikely to introduce gene selection biases.
The fifth preprocessing method considered here was imple-
mented in the supplementary software of Zaas et al. [9] and was
aimed at correcting differences between gene expression profiles of
the uninfected subjects from different experimental cohorts (i.e.,
HRV, RSV and Influenza A). This correction was performed
using all subjects within each cohort by first computing the mean
gene expression profile of the uninfected subjects within the cohort
and then subtracting this mean profile from all gene expression
profiles (i.e., infected and uninfected) in the cohort. The key
assumptions underlying this preprocessing method are that all
uninfected subjects should have similar gene expression profiles
and that the observed differences are entirely due to the so-called
Biases in Development of Molecular Signatures
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biological samples. An illustration of the effects of this preprocess-
ing method is given in the Text S1.
The sixth preprocessing method considered here is ComBat
[34], which also aims to alleviate the influence of batch effects on
the analysis of gene expression data [35]. ComBat relies on two
assumptions: (i) that all uninfected subjects should have similar
gene expression profiles and (ii) that batch effects affect gene
expression measurements in a similar way across many genes. In
ComBat, batch effects are first modeled as additive (i.e., location)
and multiplicative (i.e., scale) components of the observed gene
expression levels for each gene. These estimates are then updated
in a Bayesian framework that pools information on batch effect
estimates from all the genes in the dataset. We chose ComBat for
our evaluation due to this method’s computational efficiency and
lack of ad-hoc parameters, which makes ComBat appropriate for
application in a permutation-based framework. When applying
ComBat, the phenotype was supplied as a covariate in addition to
the cohort incidence variable. This was done in order to allow
ComBat to retain the variation in gene expression profiles that was
due to biological responses to pathogens.
Results and Discussion
A simulation study demonstrating data-analytic biases
related to signature multiplicity and biomarker
redundancy
Evaluation of data-analytic protocols in real data is challenging
due to absence of a biological gold standard describing true
interactions between genes and the phenotype. For this reason and
in order to illustrate in a controlled environment, the behavior of
the factor analysis-based gene selection method from the protocol
of Zaas et al. [9], we conducted experiments in a simulated dataset
TIED with exactly known causal relationships between variables
[14,15]. This dataset allows us to evaluate the considered data-
analytic protocol in terms of its effectiveness in extracting the
complete set of relationships between genes and the phenotype.
Identification of these relationships is essential for constructing a
comprehensive view of the underlying biological process.
When applied to TIED, factor analysis-based method extracted
only a single signature containing 30 genes, 4 of which were
causally relevant and non-redundant (X5, X10, X12 and X20),
4 were redundant given the previous set of genes (X8, X13, X14 and
X21), and 22 were irrelevant and without association with the
phenotype. (see Figure S1 for an illustration of the complete data-
generating graph of causal relationships that produced TIED
dataset). In particular, the factor analysis-based technique missed
all genes from the subset {X1,X2,X3,X11} that are causally directly
related to the phenotype. In contrast, TIE* correctly identified all
and only the 72 non-redundant molecular signatures of the
phenotype in TIED dataset. These results indicate that the factor
analysis-based protocol leads to selection of false positive and false
negative genes.
There exist many different and equally accurate
molecular signatures of the panviral phenotype
Using the TIE* algorithm, we identified 3,473 novel non-
redundant and maximally predictive signatures of acute respira-
tory viral infections in the dataset of Zaas et al., while the prior
data-analytic protocol yielded only one signature of the phenotype
[9]. On average each identified novel signature contained 11
genes, and together all signatures spanned over 60 distinct
oligonucleotide probes corresponding to 57 genes. The average
phenotype classification performance of these signatures in the
independent data of Ramilo et al. [12] was 0.92 area under the
ROC curve (AUC) with a standard deviation of 0.06 AUC.
Notably, 3,308 (or 95%) of the signatures discovered by TIE*
achieved classification performance comparable to the panviral
signature of Zaas et al. Genes that appeared in more than 20% of
the signatures are shown in Table 2. Out of these genes, only three
genes (RSAD2, IFI44L and IFI44) were present in the panviral
signature of Zaas et al. In contrast, all 12 genes comprising the
panviral signature that we previously developed [10] were among
genes listed in Table 2 (highlighted in bold). The complete list of
molecular signatures discovered by TIE* and the genes comprising
those signatures can be found in the Dataset S1 and Table S1,
respectively.
Since the phenotype is characterized by multiple molecular
signatures, focusing on a single arbitrarily chosen signature may not
yield causative biomarkers of the disease nor provide accurate
grounds for understanding pathogenesis [15]. In general, genes
comprising a single molecular signature may not be the only
determinants of the phenotype. There may exist multiple equally
informative and non-redundant gene sets that when taken together
would provide a comprehensive view of the underlying biological
process. Therefore, data-analytic protocols should extract, to the
extent possible, all molecular signatures of the phenotype.
Many genes in the previously developed ‘‘acute
respiratory viral response’’ signature are redundant
Our redundancy analysis showed that only 20 gene probes from
the 30-gene panviral signature (corresponding to 32 gene probes)
identified by the factor analysis-based gene selection method from
the data-analytic protocol of Zaas et al. [9] were non-redundant.
The following gene probes were found to be redundant (gene
names are provided in parentheses): 202672_s_at (ATF3),
218943_s_at (DDX58), 219863_at (HERC5), 214059_at (IFI44),
214453_s_at (IFI44), 204439_at (IFI44L), 204415_at (IFI6),
204747_at (IFIT3), 205483_s_at (ISG15), 205569_at (LAMP3),
202145_at (LY6E), and 202086_at (MX1). A panviral signature
constructed on the basis of the 20 remaining non-redundant genes
achieved the same predictive accuracy (1.0 AUC) in the
independent validation data of Ramilo et al. [12] as the original
signature.
It should be noted, however, that redundancy is not always
equivalent to biological irrelevance of the genes, but only implies
that the redundant genes do not carry any additional predictive
information about the phenotype beyond what’s conveyed by the
non-redundant genes. While presence of redundant genes in a
signature could potentially worsen its reproducibility and would
surely increase its manufacturing costs, in some cases it may be
desirable to explicitly engineer redundancy into a molecular
signature in order to improve its robustness for a specific
phenotype. We would argue, however, that such redundancy
should arise from a careful methodological design rather than
being an unintended consequence of applying a certain data
analytic technique.
Data preprocessing methods may bias gene selection
While the topic of microarray gene expression data normaliza-
tion has been extensively studied in prior work [31,36], the effects
on gene selection of data preprocessing after normalization remain
unclear. Below, we present a comparison of six different data
preprocessing methods using gene expression dataset of Zaas et al.
[9]. Since it is not known which genes are truly associated with the
panviral phenotype, we conducted phenotype label permutation
experiments under the null hypothesis of no association between
genes and the phenotype. The results are shown in Table 3 and
Biases in Development of Molecular Signatures
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[0,1] scaling did not bias gene selection. The average number of
significantly associated genes under each of these preprocessing
methods was 0.3 with standard error 0.091 over 10,000
permutations. However, the batch correcting procedure from
the supplementary software of Zaas et al. biased gene selection and
resulted in an average of 55.6 genes being deemed significant with
standard error 4.407. Similarly, application of the ComBat batch
correction method produced 71.3 (standard error 5.051) signifi-
cant genes on average.
We note that these results were obtained in simulated conditions
of no biological signal in the data. A study of behavior of the
considered batch correction methods under the alternative
hypothesis of presence of a biologically meaningful signal remains
an open research direction that would have to rely on biological
validation of genes selected on preprocessed data. Preliminary
results reported here suggest that the two batch correction
methods may potentially lead to an increase in the number of
false positives in the output of statistical methods for gene
selection. We hypothesize that the increased number of statistically
significant genes came as a result of decreases in within-group
variance in expression of genes in the infected and uninfected
groups of subjects after correcting for batch effects. When not
offset by a comparable decrease in differences between the groups’
mean gene expression profiles, this decrease in variance may cause
an appearance of statistically significant associations between the
phenotype and genes that were not significantly differentially
expressed before data preprocessing. We further illustrate this
behavior in Figure S2 that shows distributions of variance of gene
expression in the original (i.e., non-permuted) infected and
uninfected subjects as well as differences between mean expression
of genes in the two groups of subjects before and after
preprocessing by the supplementary software of Zaas et al. As
made evident by Figure S2, preprocessing reduced within-group
variances of gene expression while leaving differences between
group means largely unchanged. Data preprocessing by ComBat
had a very similar effect and the corresponding histograms are
shown in Figure S3.
A specific example illustrating the above effects of preprocessing
in the original (non-permuted) data is shown in Figure 1. As can be
seen in that figure, within-class variances decreased roughly five-
fold for gene RIBC2 as a result of batch correction using the
supplementary software of Zaas et al. Consequently, the p-value
produced by a two-sample t-test for differential expression
decreased from roughly 0.5 to below 10
23 causing an appearance
of a statistically significant association between gene RIBC2 and
the panviral phenotype. Although the two classes of gene
expression profiles could not be separated without errors using
only gene RIBC2 in the preprocessed data, in general, such
preprocessing may force classes to become perfectly separable as
shown using simulated data in Figure S4.
Similar effects of preprocessing were observed in a large portion
of genes in the data of Zaas et al. [9]. We applied a two-sample t-
test with FDR 0.2 [33] to identify genes statistically significantly
associated with the panviral phenotype, either before or after
preprocessing. While only 1,759 genes were significantly associ-
ated with the phenotype in the original data, the number of
significant genes in the preprocessed data was four times higher,
Table 2. Genes that appeared in more than 20% of non-redundant and maximally predictive signatures identified by TIE* for
discriminating between symptomatic and uninfected samples.
Probe ID Gene symbol Gene name Percentage of signatures participated in
201065_s_at GTF2I general transcription factor IIi 73%
213674_x_at IGHD immunoglobulin heavy constant delta 73%
214511_x_at FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) 72%
207826_s_at ID3 inhibitor of DNA binding 3, dominant negative
helix-loop-helix protein
71%
213797_at RSAD2 radical S-adenosyl methionine domain containing 2 71%
217418_x_at MS4A1 membrane-spanning 4-domains, subfamily A, member 1 70%
219471_at C13orf18 chromosome 13 open reading frame 18 69%
219112_at RAPGEF6 Rap guanine nucleotide exchange factor (GEF) 6 63%
219073_s_at OSBPL10 oxysterol binding protein-like 10 59%
219313_at GRAMD1C GRAM domain containing 1C 56%
204439_at IFI44L interferon-induced protein 44-like 42%
221234_s_at BACH2 BTB and CNC homology 1, basic leucine zipper
transcription factor 2
29%
216950_s_at FCGR1A, FCGR1C Fc fragment of IgG, high affinity Ia, receptor (CD64);
Fc fragment of IgG, high affinity Ic, receptor (CD64)
28%
207431_s_at DEGS1 degenerative spermatocyte homolog 1, lipid desaturase
(Drosophila)
25%
205049_s_at CD79A CD79a molecule, immunoglobulin-associated alpha 24%
202723_s_at FOXO1 forkhead box O1 22%
44790_s_at C13orf18 chromosome 13 open reading frame 18 22%
203413_at NELL2 NEL-like 2 (chicken) 20%
214059_at IFI44 Interferon-induced protein 44 20%
Genes highlighted in bold are those that also comprised the 12-gene panviral signature developed by applying GLL on the entire set of samples [10].
doi:10.1371/journal.pone.0020662.t002
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the supplementary software of Zaas et al. and 7,557 genes when
using ComBat. Notably, all genes that were significantly associated
with the phenotype before preprocessing remained significant after
preprocessing. Therefore, none of the genes lost their association
and 5,588 (5,798 for ComBat) genes gained association with the
phenotype as a result of preprocessing.
These findings indicate that special care has to be taken when
applying preprocessing methods for gene expression analysis.
Batch effect correction methods may be appropriate for
application in cases when significant biological differences between
samples can be ruled out. However, the cohort recruitment
protocol of Zaas et al. does not allow such biological differences to
be ruled out without additional validation. According to Zaas et al.,
the HRV cohort was recruited through an active screening
protocol at the University of Virginia, so these subjects may be a
younger, healthier group mostly composed of college students, and
are more likely to be middle to upper-middle class. The RSV
cohort was recruited and infected through Retroscreen Virology,
London, a company that specializes in clinical trials on viruses. It is
likely that the ages of the subjects are more diverse than the HRV
cohort, and perhaps the racial make-up is more diverse as well
since London has a more ethnically diverse population than
Charlottesville, Virginia. The influenza cohort was recruited and
infected through Retroscreen Virology, Brentwood, UK. Brent-
wood is 20 miles outside of London, a suburban setting. It is likely
that volunteers are more diverse in age and less racially diverse
than the London (RSV) cohort.
Given the above stated observations on the effects of batch
correction methods and due to a lack of information regarding the
causes of differences between the unexposed samples from
different viral cohorts in the data of Zaas et al. [9], we used only
the RMA normalization in our data analysis.
Molecular signatures should be developed and applied
to the same phenotype and population of subjects
The 30-gene panviral molecular signature introduced by Zaas
et al. [9] was developed specifically for differentiating between
uninfected (healthy) subjects and subjects who developed symp-
toms following a viral inoculation with either HRV, RSV, or
influenza A. In an attempt to demonstrate specificity of this
molecular signature to viral infections, Zaas et al. applied this
signature for classification of subjects with bacterial and viral
(Influenza A) infections in the data of Ramilo et al. [12] and
reported a predictive accuracy of roughly 0.94 AUC [9]. This
interesting result raises the following question that we address
below: Why a molecular signature developed for one task
(differentiating between uninfected subjects and subjects with viral infections)
was successful in performing another task (differentiating between
subjects with bacterial and viral infections)?
Table 3. Effects of preprocessing methods on gene selection
under the null hypothesis of no association between genes
and the panviral phenotype in the acute respiratory viral
infections dataset [9].
Preprocessing Number of significant probes
Mean St. Dev. 95% Interval
No preprocessing 0.3 9.1 0.0 0.0
Center (subtract global mean) 0.3 9.1 0.0 0.0
Standardize (subtract global
mean and divide by stdev)
0.3 9.1 0.0 0.0
Scale each probe to [0,1] 0.3 9.1 0.0 0.0
Batch correction from the
supplementary software of
Zaas et al. [9]
55.6 440.7 0.0 287.5
ComBat 71.3 505.1 0.0 707.0
The phenotype variable was randomly permuted 10,000 times. On each
permutation, we applied a given preprocessing method and then performed
gene selection using a two-sample t-test with the false discovery rate (FDR)
correction at level 0.2 [32,33].
doi:10.1371/journal.pone.0020662.t003
Figure 1. Effects of preprocessing by the supplementary software of Zaas et al. [9] on real gene expression data. Gene expression
profiles of the uninfected subjects are shown in blue staggered on top of the profiles of the infected subjects highlighted with red. The blue and red
vertical line segments denote locations of the mean expression in the uninfected and infected groups, respectively. Likewise, blue and red horizontal
line segments emanating in both directions from the means denote one standard deviation within the uninfected and infected groups, respectively.
P-values produced by a two-sample t-test with unequal variances are shown in parenthesis.
doi:10.1371/journal.pone.0020662.g001
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et al. in the space of the first two principal components obtained
from genes that constituted the panviral signature of Zaas et al.
The solid line is an approximation of the molecular signature
(classifier) of Zaas et al. This signature would classify subjects to the
left of the line as uninfected (healthy) whereas subjects to the right
of the line would be classified as virally infected. Figure 2 also
demonstrates that the same molecular signature can incidentally
be used to accurately differentiate between subjects with bacterial
and viral infections from the dataset of Ramilo et al., thus
confirming the finding of Zaas et al. However, this result is due to a
lucky choice of genes in the molecular signature of Zaas et al. that
was either helped by redundant genes for the viral phenotype
(recall that only 20 gene probes were non-redundant) and/or
could have been informed by other criteria and procedures not
reported in the original publication. When we substituted factor
analysis-based gene selection in the protocol of Zaas et al. with
GLL, which by design yields only non-redundant genes for the
viral phenotype, predictive accuracy for the bacterial vs. viral
classification task was reduced to 0.60 AUC. This indicates that
the finding of Zaas et al. is method-dependent. Moreover, the
following subsection shows that the methodology employed by
Zaas et al. for evaluating the specificity of their molecular signature
to viral infections does not generalize to other datasets.
These results demonstrate that molecular signatures developed
for one phenotype and population of subjects and applied to
another phenotype and/or population are highly problematic.
There is no reason to undertake this risk when one can apply
supervised techniques to data for the same phenotype and
population of subjects. Specifically, in case of performing
classification of virally and bacterially infected subjects, one would
need to develop a new molecular signature using gene expression
profiles of patients with viral and bacterial infections. Although
this recommendation may seem obvious, current practices in
clinical research suggest otherwise. For instance, extrapolation of
results obtained using animal models to humans has been a de-
facto methodology underlying much of translational clinical and
biomedical research. However, animal models are often not
representative of the effects an intervention may have in humans
[37–39]. Therefore, in cases when applications of a model in a
different organism or phenotype cannot be justified biologically,
data-analytic protocols should be applied to construct organism-
and phenotype-specific models.
Conclusions of this case study generalize beyond the
domain of acute respiratory viral infections
Below we demonstrate that the major findings of this case study
pertaining to data analytic protocols generalize to other domains
and datasets. We analyze a microarray gene expression dataset
that was used for development of molecular signatures for
diagnosis of Candidemia [11]. We chose this dataset because it
has been previously analyzed with a protocol that is very similar to
the one applied for development of acute respiratory viral infection
signatures [9]. Note that since the Candidemia dataset was
collected from a different organism than the acute respiratory viral
response dataset and because Candidemia is a drastically different
disease than respiratory infections, we do not draw comparisons
between genes comprising molecular signatures of Candidemia
and genes comprising molecular signatures of the panviral
Figure 2. Visualization of subjects in the dataset from [12] in the space of the first two principal components of the panviral
signature of Zaas et al. The solid line is an approximation of the molecular signature (classifier) of Zaas et al.; subjects to the left of this line are
classified as uninfected (healthy) and subjects to the right are classified as virally infected (Influenza A). Blue and red gradient highlighting
corresponds to the regions where the majority of bacterial and viral profiles belong, respectively. Green highlighting shows the area with uninfected
(healthy) profiles.
doi:10.1371/journal.pone.0020662.g002
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molecular signatures developed in the Candidemia dataset.
By employing factor analysis, the original study showed the
existence of a single 82-gene signature that accurately classified
Candidemia-infected samples versus healthy controls [11]. Using the
TIE* algorithm, we identified 2,922 novel non-redundant and
maximally predictive signatures of Candidemia in the same set of
training samples. On average, each novel signature contained 14
genes,andtogetherallsignaturesspannedover65distinctgenes.The
average phenotype classification performance of these signatures in
thetestingsetofsampleswas0.996AUCwithastandarddeviationof
0.01 AUC. Notably, 2,513 (or 86%) of the signatures discovered by
TIE* achieved AUC=1.0. The complete list of molecular signatures
discovered byTIE* and the genescomprisingthosesignaturescanbe
found in Dataset S2 and Table S2, respectively. Interestingly, there
were no genes in common between the Candidemia signature of
Zaas et al. [11] and multiple signatures indentified by TIE*.
We have further assessed redundancy within the 82-gene
signature and found 79 redundant and only 3 non-redundant gene
probes: 1449453_at (Bst1), 1424254_at (Ifitm1), 1421304_at
(Klra2). A molecular signature developed on the basis of these
three non-redundant genes achieved predictive accuracy of 1.0
AUC in the independent validation data, which is the same as the
accuracy of the original 82-gene signature.
Next, we observed that the effects of batch correctionmethods on
gene selection extend beyond the acute respiratory viral infections
dataset and that such preprocessing also biases gene selection in the
Candidemia dataset. In this case, there were two experimental
batches corresponding to samples from the C. albicans and S. aureus
cohorts, respectively. Each batch contained samples from infected
and uninfected mice. The phenotype variable differentiated
between infected and uninfected samples. Experiments conducted
under the null hypothesis of no association between the genes and
the phenotype produced results consistent with the ones obtained in
the acute respiratory viral infections dataset. As can be seen in
Table 4, the average number of significantly associated genes under
no preprocessing, centering, standardization and [0,1] scaling was
82.6 with standard error 6.407 over 10,000 permutations. The
number of significantly associated genes increased to an average of
221.8 with standard error 10.98 when preprocessing from the
supplementary software of Zaas et al. was applied. Similarly,
preprocessing by ComBat resulted in 253.2 (standard error 11.743)
significant genes on average.
Application of the two-sample t-test with FDR 0.2 to the
original Candidemia dataset [11] (i.e., raw probe data after RMA
normalization) produced 11,256 genes that were significantly
associated with the phenotype differentiating between bacterially
infected and uninfected samples. However, the same experiment
in the data after preprocessing resulted in 13,590 significantly
associated genes when using the supplementary software of Zaas
et al. and 13,850 genes after preprocessing with ComBat. Similarly
to the results obtained in the acute respiratory viral infections
dataset, none of the genes in the Candidemia dataset lost their
association and 2,334 and 2,594 genes gained association with the
phenotype as a result of preprocessing with the two batch
correction methods.
Finally, we applied the 82-gene molecular signature of
Candidemia to classify S. aureus bacteremia and C. albicans in the
independent set of 27 samples (18 C. albicans and 9 S. aureus) [11].
This experiment was designed to mimic the signature specificity
validation step from the original data-analytic protocol of Zaas
et al. [9]. In this case, however, performance of the Candidemia
signature did not generalize to the different phenotype, resulting in
classification accuracy statistically indistinguishable from that of a
signature with no predictive power (0.5 AUC). In addition, the
study [11] has reported the ability to accurately classify the two
bloodstream infections using a new molecular signature that was
specifically designed for that classification task. Taken together
with the results of our analysis, this further accentuates the need to
develop and apply molecular signatures to the same phenotype
and population of subjects.
Conclusion and operational recommendations
The science and technology of molecular signatures is
positioned to play a crucial role in the advancement of
personalized medicine and clinical diagnostics. Data-analytics is
a central component of molecular signature development. On the
basis of many recent meta-analyses and re-analyses of prior
experiments it becomes evident that biased data analytics are
emerging as a major obstacle for progress in personalized medicine
[3–7,40]. Improving data-analytics for development of clinical-
grade molecular signatures requires detailed understanding of the
data analysis biases and development of strategies to avoid them.
In this work, we presented a case study evaluating a data-analytic
protocol that has recently led to development of an important 30-
gene signature of acute respiratory viral infections [9] and also
informed the development of the 82-gene signature of Candidemia
[11]. Conclusions of this study, however, are not specific to the
analysis of acute respiratory viral infections and generalize to other
domains as was made evident by validation of our results in
additional data. Below we summarize our key findings and
operational recommendations to data analysts based on empirical
results reported in this paper.
First, we showed the existence of many different and equally
accurate molecular signatures of the phenotypes. Therefore, in
order to obtain comprehensive and accurate grounds for under-
standing pathogenesis, data-analytic protocols should extract, to the
extent possible, all molecular signatures of a phenotype rather than
focusing on an arbitrarily chosen single signature. Whenever
possible, analysis that separates statistical instability from intrinsic
information equivalency should be undertaken [15]. Second, our
results demonstrate the presence of redundant genes in prior
molecular signatures and highlight the need for routine assessment
Table 4. Effects of preprocessing methods on gene selection
under the null hypothesis of no association between genes
and the bacterial phenotype in the Candidemia dataset [11].
Preprocessing Number of significant probes
Mean St. Dev. 95% Interval
No preprocessing 82.6 640.7 0.0 607.0
Center (subtract global mean) 82.6 640.7 0.0 607.0
Standardize (subtract global
mean and divide by stdev)
82.6 640.7 0.0 607.0
Scale each probe to [0,1] 82.6 640.7 0.0 607.0
Batch correction from the
supplementary software of
Zaas et al. [9]
221.8 1098.0 0.0 3543.5
ComBat 253.2 1174.3 0.0 3991.5
The phenotype variable was randomly permuted 10,000 times. On each
permutation, we applied a given preprocessing method and then performed
gene selection using a two-sample t-test with the false discovery rate (FDR)
correction at level 0.2 [32,33].
doi:10.1371/journal.pone.0020662.t004
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phenotype. Generally, if some genes are found to be redundant,
they can be excluded from the molecular signature, because such
genes do not contribute additional predictive information about the
phenotype and have the potential to worsen signature reproduc-
ibility and increase its manufacturing costs. In certain cases,
however, it may be necessary to explicitly engineer redundancy
into a molecular signature in order to improve its robustness for a
specific phenotype. Such redundancy should arise from a careful
methodological design rather than being an unintended conse-
quence of applying a certain data analytic technique. Third, we
showed that data preprocessing may bias gene selection. It is
therefore necessary to assess the effects of any preprocessing and
other steps of data-analytic protocols on selection of genes.
Furthermore, subsequent analyses should not assume that the same
preprocessing would be appropriate in a different setting. Finally,
molecular signatures should be developed and applied to the same
phenotype and population of subjects. Failure to do so may result in
spurious findings and non-reproducible data-analytic protocols, as
was demonstrated in the present study. The methodology and
results presented in this work combined with previously established
bias avoidance strategies aim to further advance the process of
development of clinically successful molecular signatures by
improving the associated data-analytic protocols.
Supporting Information
Figure S1 Data generating graph that was used for
evaluation of methods for development of molecular
signatures under the condition of signature multiplicity.
There are 1,000 variables in the graph (999 genes and a
phenotypic response variable T). Genes that contain exactly the
same information about T are highlighted with the same color, e.g.
genes X12, X13, and X14 provide exactly the same information
about T and are thus interchangeable for prediction of T.T h e r e
are 72 distinct molecular signatures of the phenotype T (i.e., sets
of non-redundant genes that carry maximal predictive informa-
tion about the phenotype and render it statistically independent
of all other genes). Each of these signatures carries equivalent
information about the phenotype and spans over 5 genes: gene
X10 and one gene from each of the four subsets {X1,X2,X3,X11},
{X5,X9}, {X12,X13,X14}a n d{ X19,X20,X21}.
(TIF)
Figure S2 Distributions of variance in the infected and
uninfected subjects (top two figures) and differences
between means of their gene expression profiles (bottom)
before and after preprocessing by the supplementary
software of Zaas et al. [9]. The distribution of variance is
shifted to the left (i.e., to smaller values) as a result of
preprocessing, while the distribution of differences between means
is largely unaffected.
(TIF)
Figure S3 Distributions of variance in the infected and
uninfected subjects (top two figures) and differences
between means of their gene expression profiles
(bottom) before and after preprocessing by ComBat
[34]. The distribution of variance is shifted to the left (i.e., to
smaller values) as a result of preprocessing, while the distribution
of differences between means is largely unaffected.
(TIF)
Figure S4 Effects of preprocessing method from the
supplementary software of Zaas et al. [9] on simulated
data. Gene expression profiles of the uninfected subjects are
shown in blue staggered on top of the profiles of the infected
subjects highlighted with red. The blue and red vertical line
segments denote locations of the mean expression in the unin-
fected and infected groups, respectively. Likewise, blue and red
horizontal line segments emanating in both directions from the
means denote one standard deviation within the uninfected and
infected groups, respectively. P-values produced by a two-sample t-
test with unequal variances are shown in parenthesis.
(TIF)
Table S1 The complete list of genes participating in the 3,473
non-redundant and maximally predictive molecular signatures
discovered by the TIE* algorithm in the data of Zaas et al. [9] for
discriminating symptomatic from uninfected samples. Genes
highlighted in bold are those that also comprised the 12-gene
panviral signature developed by Statnikov et al. [10] by applying
GLL on the entire set of samples.
(PDF)
Table S2 The complete list of genes participating in the 2,922
non-redundant and maximally predictive molecular signatures
discovered by TIE* in the data of Zaas et al. [11] for discriminating
between Candidemia-infected samples and healthy controls.
Genes highlighted in bold are those that also comprised a 14-
gene signature developed by applying GLL in the same data.
(PDF)
Dataset S1 The complete list of molecular signatures discovered
by TIE* for the panviral phenotype from the data of Zaas et al. [9].
(CSV)
Dataset S2 The complete list of molecular signatures of Candi-
demia discovered by TIE* in the data of Zaas et al. [11].
(CSV)
Text S1 An illustration of the effects of a preprocessing proce-
dure from the supplementary software of Zaas et al. [9].
(PDF)
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